Very unlikely FDA to recommend running human trials when they had every opportunity to do so last year. Plus why would FDA spend a substantial amount of time inspecting the 4 plants in China if they had the notion of recommending running human trials on the horizon?
If the ass-backward recommendation of running clinical trials is made now it would be devastating to the immediate and near-term share price because I don't think anyone close to the stock anticipates that being a real possibility.
Market Data 
Markets 
AI
